Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer

BACKGROUND: ALK‐tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK‐positive non‐small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Thorac Cancer
Huvudupphovsmän: Kang, Jin, Chen, Hua‐Jun, Zhang, Xu‐Chao, Su, Jian, Zhou, Qing, Tu, Hai‐Yan, Wang, Zhen, Wang, Bin‐Chao, Zhong, Wen‐Zhao, Yang, Xue‐Ning, Chen, Zhi‐Hong, Ding, Yan, Wu, Xue, Wang, Mei, Fu, Jian‐Gang, Yang, Zhenfan, Zhang, Xian, Shao, Yang W., Wu, Yi‐Long, Yang, Jin‐Ji
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons Australia, Ltd 2018
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6119621/
https://ncbi.nlm.nih.gov/pubmed/29978950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12791
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk